Kamada Ltd
NASDAQ:KMDA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its 3-Year Average (23.6), the stock would be worth $8.28 (1% upside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 23.4 | $8.2 |
0%
|
| 3-Year Average | 23.6 | $8.28 |
+1%
|
| 5-Year Average | 20.5 | $7.19 |
-12%
|
| Industry Average | 23.2 | $8.11 |
-1%
|
| Country Average | 19.1 | $6.69 |
-18%
|
Forward P/E
Today’s price vs future net income
| Today's Market Cap | Net Income | Forward P/E | ||
|---|---|---|---|---|
|
$477.6m
|
/ |
Jan 2026
$20.2m
|
= |
|
|
$477.6m
|
/ |
Dec 2026
$29.7m
|
= |
|
|
$477.6m
|
/ |
Dec 2027
$34.9m
|
= |
|
|
$477.6m
|
/ |
Dec 2028
$41.2m
|
= |
|
Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| IL |
|
Kamada Ltd
NASDAQ:KMDA
|
473m USD | 23.4 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
348.9B USD | 83.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
183.4B USD | 23.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
158.5B USD | 18.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.2B USD | 27.4 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.7B USD | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR | 37.9 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
63.6B AUD | 30.3 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 12.9 |
| Median | 19.1 |
| 70th Percentile | 29.8 |
| Max | 1 624.2 |
Other Multiples
Kamada Ltd
Glance View
Kamada Ltd. engages in the development and production of pharmaceutical products. The firm uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
